Jaguar’s name is now Jaguar Health!

On Monday, July 31, the merger of Jaguar Animal Health and Napo Pharmaceuticals became effective. Napo focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global human marketplace from sustainably derived plants used traditionally in rainforest areas. As a result of the merger, Jaguar’s name is now Jaguar Health, Inc., and Napo is a wholly-owned subsidiary of Jaguar, focused on the continuing commercialization of its Mytesi® (crofelemer) product, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Serving a Broad Range of Species

Our products will serve companion animals,
horses and production animals with prescription
and non-prescription products globally.

Buy Neonorm Foal Buy Neonorm Calf

Access to Powerful, Natural Compounds

Jaguar maintains an exclusive, worldwide
license to a large medicinal plant library for
veterinary applications.

Buy Neonorm Foal Buy Neonorm Calf

Committed to Animal Health

We are focused on the development &
commercialization of animal health
solutions that are naturally derived
& sustainably harvested.

Buy Neonorm Foal Buy Neonorm Calf

New Anti-Diarrheal Product for Foals
Is your current foal diarrhea product supported
by clinical evidence? (We suspect not)

Buy Neonorm Foal

Naturally derived health solutions for humans and animals around the world

About Us

In conjunction with Napo Pharmaceuticals, our new subsidiary, Jaguar Health is focused on developing and commercializing a range of first-in-class gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals.


We are committed to identifying human and animal health market opportunities where we can develop targeted products that leverage our broad intellectual property portfolio, deep pipeline and extensive botanical library.


July 31, 2017: The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective
Jul. 27, 2017: Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger
Jul 24, 2017: New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment

MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information